Mapping Therapeutic Regulatory T Cell Fate with MRI: Current Strategies and Translational Outlook.

Yu Ping, Lydia Chen, Jacob Joel Hoenig, Xiaohan Yang, Fanny Chapelin

Abstract readReview

In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yu PingShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0009-0000-7977-9472

Lydia ChenShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0009-0006-7926-3066

Jacob Joel HoenigShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0009-0008-5120-8027

Xiaohan YangShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA.

Fanny ChapelinShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-9340-743X

Funding

Magnetic resonance imaging methods to capture tolerogenic cell therapy fate in preclinical and ex vivo human transplant modelsR01EB039044 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Fanny Chapelin · 2026 to 2026

$564k

NIBIB NIH HHS R01EB039044

6 · The paper itself

Abstract

Adoptive cell therapies, and more specifically, regulatory T cell (Treg) therapies, have shown significant therapeutic promise across multiple immune-mediated diseases including graft-versus-host disease (GvHD), solid organ transplant (SOT) rejection, and autoimmune diseases. One key challenge is the lack of insight into the biodistribution and fate of adoptively transferred T cells and Tregs in living organisms. These uncertainties delay progress on establishing optimal dosage(s), infusion timing and route, as well as investigations into off-target effects. Magnetic resonance imaging (MRI) cell tracking is particularly beneficial in this setting because it enables real-time, deep-tissue coverage without ionizing radiation. In this review, we compare existing MRI T cell tracking strategies using iron oxide particles and fluorinated agents. We describe preclinical and clinical applications of MRI for cell therapy tracking and provide a perspective on the potential impact on the field.

Indexed as

adoptive cell therapyfluorine-19 MRIgraft-versus-host diseaseMRI cell trackingregulatory T cellssuperparamagnetic iron oxidetransplantation

Identifiers

PMID42274698

DOI10.3390/nano16110691

PMCPMC13258234

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.